1,445 Shares in Penumbra, Inc. (NYSE:PEN) Bought by Captrust Financial Advisors

Captrust Financial Advisors purchased a new position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,445 shares of the company's stock, valued at approximately $343,000.

A number of other institutional investors have also bought and sold shares of the company. UMB Bank n.a. grew its position in shares of Penumbra by 57.4% during the 4th quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $46,000 after acquiring an additional 70 shares during the period. Hurley Capital LLC bought a new position in shares of Penumbra during the 4th quarter valued at approximately $56,000. Huntington National Bank grew its position in shares of Penumbra by 138.7% during the 4th quarter. Huntington National Bank now owns 265 shares of the company's stock valued at $63,000 after acquiring an additional 154 shares during the period. Mather Group LLC. grew its position in shares of Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company's stock valued at $73,000 after acquiring an additional 208 shares during the period. Finally, Jones Financial Companies Lllp lifted its stake in shares of Penumbra by 25.0% during the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock valued at $89,000 after buying an additional 75 shares in the last quarter. Institutional investors own 88.88% of the company's stock.

Penumbra Stock Up 0.7%

NYSE PEN traded up $1.97 during midday trading on Monday, hitting $268.72. 235,921 shares of the company traded hands, compared to its average volume of 443,992. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The company has a market cap of $10.41 billion, a PE ratio of 790.35, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53. The company's 50-day simple moving average is $279.45 and its 200-day simple moving average is $265.62. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00.

Penumbra (NYSE:PEN - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $324.14 million for the quarter, compared to the consensus estimate of $315.72 million. During the same period in the previous year, the business earned $0.41 EPS. The firm's revenue for the quarter was up 16.3% on a year-over-year basis. As a group, equities research analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Bridget O'rourke sold 100 shares of the firm's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $286.15, for a total transaction of $28,615.00. Following the sale, the director now directly owns 5,423 shares in the company, valued at $1,551,791.45. This trade represents a 1.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas Wilder sold 360 shares of Penumbra stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $264.58, for a total value of $95,248.80. Following the completion of the sale, the director now owns 4,533 shares in the company, valued at approximately $1,199,341.14. The trade was a 7.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 176,696 shares of company stock worth $50,207,745 in the last 90 days. Insiders own 4.20% of the company's stock.

Analyst Ratings Changes

PEN has been the topic of a number of recent research reports. Robert W. Baird upped their price target on shares of Penumbra from $316.00 to $325.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Wall Street Zen cut shares of Penumbra from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Bank of America assumed coverage on shares of Penumbra in a research report on Friday, March 14th. They set a "buy" rating and a $320.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on shares of Penumbra from $230.00 to $285.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. Finally, Stifel Nicolaus set a $318.00 price objective on shares of Penumbra and gave the company a "buy" rating in a research report on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Penumbra presently has an average rating of "Moderate Buy" and an average price target of $302.40.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.